STENTS HAVING CONTROLLED ELUTION

• US 20100272778A1
• Filed: 04/16/2010
• Published: 10/28/2010
• Est. Priority Date: 04/17/2007
• Status: Active Grant

• Current Assignee: Micell Medtech Incorporated
• Original Assignee: Micell Technologies Inc.
• Inventors: McClain, James B., Taylor, Douglas
• Granted Patent: US 9,433,516 B2
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/204 with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/426 Immunomodulating agents, i.e. cytokines, interleukins, interferons
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/63 Crystals
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 31/022 Metals or alloys
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.

Claims

1. A device comprising

a. a stent;

and

b. a coating on the stent;

wherein the coating comprises at least one bioabsorbable polymer and at least one active agent;

wherein the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the stent and wherein 50% or less of the total amount of active agent in the coating is released after 24 hours in vitro elution.

2. The device of claim 1, wherein in vitro elution is carried out in a 1:

1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37°

C.;

wherein the amount of active agent released is determined by measuring UV absorption.

3. The device of claim 2 wherein UV absorption is detected at 278 nm by a diode array spectrometer.

4. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by cluster secondary ion mass spectrometry (cluster SIMS).

5. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by generating cluster secondary ion mass spectrometry (cluster SIMS) depth profiles.

6. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by time of flight secondary ion mass spectrometry (TOF-SIMS).

7. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by atomic force microscopy (AFM).

8. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by X-ray spectroscopy.

9. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by electronic microscopy.

10. The device of claim 1, wherein presence of active agent on at least a region of the surface of the coating is determined by Raman spectroscopy.

11. The device of claim 1, wherein between 25% and 45% of the total amount of active agent in the coating is released after 24 hours in vitro elution in a 1:

1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37°

C.;

wherein the amount of the active agent released is determined by measuring UV absorption at 278 nm by a diode array spectrometer.

12. The device of claim 1, wherein the active agent is at least 50% crystalline.

13. The device of claim 1, wherein the active agent is at least 75% crystalline.

14. The device of claim 1, wherein the active agent is at least 90% crystalline.

15. The device of claim 1, wherein the polymer comprises a PLGA copolymer.

16. The device of claim 1, wherein the coating comprises a first PLGA copolymer with a ratio of about 40:

60 to about 60;

40 and a second PLGA copolymer with a ratio of about 60;

40 to about 90;

10.

17. The device of claim 1, wherein the coating comprises a first PLGA copolymer having a molecular weight of about 10 kD and a second polymer is a PLGA copolymer having a molecular weight of about 19 kD.

18. The device of claim 1, wherein the bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:

SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid).

19. The device of claim 1, wherein the stent is formed of stainless steel material.

20. The device of claim 1, wherein the stent is formed of a material comprising a cobalt chromium alloy.

21. The device of claim 1, wherein the stent is formed from a material comprising the following percentages by weight:

about 0.05 to about 0.15 C, about 1.00 to about 2.00 Mn, about 0.04 Si, about 0.03 P, about 0.3 S, about 19.0 to about 21.0 Cr, about 9.0 to about 11.0 Ni, about 14.0 to about 16.00 W, about 3.0 Fe, and Bal. Co.

22. The device of claim 1, wherein the stent is formed from a material comprising at most the following percentages by weight:

about 0.025 C, about 0.15 Mn, about 0.15 Si, about 0.015 P, about 0.01 S, about 19.0 to about 21.0 Cr, about 33 to about 37 Ni, about 9.0 to about 10.5 Mo, about 1.0 Fe, about 1.0 Ti, and Bal. Co.

23. The device of claim 1, wherein the stent is formed from a material comprising L605 alloy.

24. The device of claim 1, wherein the stent has a thickness of from about 50% to about 90% of a total thickness of the device.

25. The device of claim 1, wherein the device has a thickness of from about 20 μ

m to about 500 μ

m.

26. The device of claim 1, wherein the stent has a thickness of from about 50 μ

m to about 80 μ

m.

27. The device of claim 1, wherein the coating has a total thickness of from about 5 μ

m to about 50 μ

m.

28. The device of claim 1, wherein the device has an active agent content of from about 5 μ

g to about 500 μ

g.

29. The device of claim 1, wherein the device has an active agent content of from about 100 μ

g to about 160 μ

g.

30. The device of claim 1, wherein the active agent is selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof.

31. The device of claim 1, wherein the active agent is selected from one or more of sirolimus, everolimus, zotarolimus and biolimus.

32. The device of claim 1, wherein the active agent comprises a macrolide immunosuppressive (limus) drug.

33. The device of claim 32, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′

-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′

-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′

-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′

-en-1′

-yl]-rapamycin, (2′

;

E,4′

S)-40-O-(4′

,5′

-Dihydroxypent-2′

-en-1′

-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin 40-O-(6-Hydroxy)hexyl-rapamycin 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′

-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′

-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′

,5′

-Dicarboethoxy-1′

,2′

,3′

-triazol-1′

-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.

34. A device comprising

a. a stent;

and

b. a coating on the stent;

wherein the coating comprises at least one polymer and at least one active agent;

wherein the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the stent and wherein between 25% and 50% of the total amount of active agent in the coating is released after 24 hours in vitro elution.

35. The device of claim 34, wherein the polymer comprises is at least one of:

a fluoropolymer, PVDF-HFP comprising vinylidene fluoride and hexafluoropropylene monomers, PC (phosphorylcholine), Polysulfone, polystyrene-b-isobutylene-b-styrene, PVP (polyvinylpyrrolidone), alkyl methacrylate, vinyl acetate, hydroxyalkyl methacrylate, and alkyl acrylate.

36. The device of claim 35, wherein the alkyl methacrylate comprises at least one of methyl methacrylate, ethyl methacrylate, propyl methacrylate, butyl methacrylate, hexyl methacrylate, octyl methacrylate, dodecyl methacrylate, and lauryl methacrylate;

and wherein the alkyl acrylate comprises at least one of methyl acrylate, ethyl acrylate, propyl acrylate, butyl acrylate, hexyl acrylate, octyl acrylate, dodecyl acrylates, and lauryl acrylate.

37. The device of claim 34, wherein the polymer is not a polymer selected from:

PBMA (poly n-butyl methacrylate), Parylene C, and polyethylene-co-vinyl acetate.

38. The device of claim 34, wherein the polymer comprises a durable polymer.

39. The device of claim 34, wherein the polymer comprises a bioabsorbable polymer.

40. The device of claim 39, wherein the bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:

SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid).

41. The device of claim 34, wherein in vitro elution is carried out in a 1:

1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37°

C.;

wherein the amount of active agent released is determined by measuring UV absorption.

42. The device of claim 34, wherein the active agent is at least 50% crystalline.

43. The device of claim 34, wherein the active agent is at least 75% crystalline.

44. The device of claim 34, wherein the active agent is at least 90% crystalline.

45. The device of claim 34, wherein the stent is formed of at least one of stainless steel material and a cobalt chromium alloy.

46. The device of claim 34, wherein the stent has a thickness of from about 50% to about 90% of a total thickness of the device.

47. The device of claim 34, wherein the device has a thickness of from about 20 μ

m to about 500 μ

m.

48. The device of claim 34, wherein the stent has a thickness of from about 50 μ

m to about 80 μ

m.

49. The device of claim 34, wherein the coating has a total thickness of from about 5 μ

m to about 50 μ

m.

50. The device of claim 34, wherein the device has an active agent content of from about 5 μ

g to about 500 μ

g.

51. The device of claim 34, wherein the device has an active agent content of from about 100 μ

g to about 160 μ

g.

52. The device of claim 34, wherein the active agent is selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof.

53. The device of claim 34, wherein the active agent comprises a macrolide immunosuppressive (limus) drug.

54. The device of claim 53, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′

-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′

-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′

-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′

-en-1′

-yl]-rapamycin, (2′

;

E,4′

S)-40-O-(4′

,5′

-Dihydroxypent-2′

-en-1′

-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin 40-O-(6-Hydroxy)hexyl-rapamycin 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′

-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′

-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′

,5′

-Dicarboethoxy-1′

,2′

,3′

-triazol-1′

-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.